Corium International (NASDAQ:CORI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Friday.

According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “

A number of other equities research analysts have also recently issued reports on the company. Needham & Company LLC boosted their price objective on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, November 20th. HC Wainwright set a $15.00 price objective on Corium International and gave the stock a “buy” rating in a report on Friday, November 17th. Jefferies Group set a $10.00 price objective on Corium International and gave the stock a “buy” rating in a report on Sunday, October 29th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price target on shares of Corium International in a research report on Friday, December 22nd. Finally, ValuEngine upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $12.86.

Corium International (NASDAQ:CORI) opened at $9.61 on Friday. Corium International has a 1-year low of $2.67 and a 1-year high of $12.32. The company has a current ratio of 7.04, a quick ratio of 6.80 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $359.33, a PE ratio of -5.75 and a beta of 1.27.

In other Corium International news, major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $11.05, for a total transaction of $1,657,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 868,100 shares of company stock valued at $9,538,781. Company insiders own 46.50% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Stonepine Capital Management LLC acquired a new position in shares of Corium International during the second quarter worth $3,085,000. State Street Corp acquired a new position in shares of Corium International during the second quarter worth $1,840,000. Bank of New York Mellon Corp increased its holdings in shares of Corium International by 33.7% during the third quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 22,285 shares in the last quarter. EAM Investors LLC acquired a new position in shares of Corium International during the second quarter worth $563,000. Finally, TIAA CREF Investment Management LLC acquired a new position in shares of Corium International during the second quarter worth $411,000. Institutional investors own 89.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Corium International (CORI) Rating Lowered to Sell at Zacks Investment Research” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/31/corium-international-cori-rating-lowered-to-sell-at-zacks-investment-research.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Stock Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related stocks with our FREE daily email newsletter.